A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Name: A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
License: Public Domain

Seagen Inc.

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

disease

disease, hodgkin

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 283043
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.